Live feed08:00:00·37dPRReleasevia QuantisnowSamsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026ByQuantisnow·Wall Street's wire, on your screen.HROW· Harrow Inc.Health Care
